Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion ...

SALT LAKE CITY – Recursion, a clinical-stage TechBio company listed on NASDAQ: RXRX, has announced the appointment of two new members to its Board of Directors. Namandjé Bumpus, Ph.D., and Elaine Sun ...

SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical stage company specializing in drug discovery with a market capitalization of $2.28 billion, has received regulatory clearance to ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

Abstract: Implementation of the Greatest Common Divisor (GCD) for two-orders of resolution improvement in single-point and multi-point fiber refractometer is ...

Successfully merging a pull request may close this issue.